Y Intercept Hong Kong Ltd Invests $368,000 in Lineage Cell Therapeutics, Inc. $LCTX

Y Intercept Hong Kong Ltd purchased a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 405,043 shares of the company’s stock, valued at approximately $368,000. Y Intercept Hong Kong Ltd owned 0.18% of Lineage Cell Therapeutics at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in LCTX. Rhumbline Advisers lifted its position in Lineage Cell Therapeutics by 9.9% during the first quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock valued at $91,000 after acquiring an additional 18,092 shares during the last quarter. Kapitalo Investimentos Ltda purchased a new position in Lineage Cell Therapeutics in the second quarter worth $25,000. Cannon Global Investment Management LLC acquired a new position in shares of Lineage Cell Therapeutics during the second quarter worth $30,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Lineage Cell Therapeutics by 20.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 503,193 shares of the company’s stock valued at $227,000 after purchasing an additional 86,970 shares during the last quarter. Finally, Ground Swell Capital LLC purchased a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter valued at $95,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a research report on Wednesday, August 27th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Lineage Cell Therapeutics currently has an average rating of “Buy” and a consensus price target of $4.25.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX opened at $1.76 on Friday. The company has a market cap of $401.91 million, a price-to-earnings ratio of -9.78 and a beta of 1.77. The stock’s fifty day moving average price is $1.60 and its 200 day moving average price is $1.10. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.37 and a 1 year high of $2.09.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). The firm had revenue of $3.68 million for the quarter, compared to analyst estimates of $2.30 million. Lineage Cell Therapeutics had a negative return on equity of 20.00% and a negative net margin of 374.84%. Research analysts expect that Lineage Cell Therapeutics, Inc. will post -0.12 earnings per share for the current year.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.